Immuno-

Oncology
Drug

Changing the standard of
cancer treatment by bringing
Korea's 1st immune-oncology drug

PLATFORM

  • Precise Cancer
    cell Attack

    The immune system accurately recognizes and attacks only cancer cells, and minimizes damage to normal cell.

    VIEW MORE
  • Prevent a Continuous Recurrence

    With cancer cell memory, responds quickly to recurrence and maintains a continuous Cancer treatment effect

    VIEW MORE
  • Excellent
    Adaptability

    Continuously adapts and attacks cancer cell Mutations to improve cancer treatment sustainability

    VIEW MORE

PIPELINE

IMC-001

PD-L1 Antibody
IMC-002

CD47 Antibody
IMC-201

CD47&PD-L1 Bispecific Antibody
IMC-002

CD47 Antibody
IMC-201

CD47&PD-L1 Bispecific Antibody

MERIT

ImmuneOncia has demonstrated superior
efficacy in a variety of carcinomas

With optimized targeting and differentiated strategies,
We present a new paradigm in the development of immuno-oncology drugs.

  • MERIT 02
    Development of Immuno-oncology drug to target T Cell and Macrophage
  • MERIT 01
    Optimized lead selection and Rapid pre-clinical development
  • MERIT 03
    Differentiated strategies of clinical development

NEWS & NOTICE

CAREER

Come Innovate
With Us!

Join us and grow together with ImmuneOncia

Go to Careers